AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Pro Medicus (PME) sees a significant price adjustment in early 2025.
- James Hardie Industries (JHX) maintains robust performance metrics despite distance from its annual high.
- Both companies showcase strong growth and innovation in their respective sectors.
In a recent analysis of the stock market trends, two noteworthy companies on the ASX have been drawing attention for different reasons. Pro Medicus Ltd (ASX:PME), a pioneer in radiology IT solutions, and James Hardie Industries plc (ASX:JHX), a leading global building solutions provider, each present unique facets of their operation and financial health that merit a closer look.
Pro Medicus Ltd (ASX:PME): Despite a notable decline of 25.4% in its share price since the beginning of 2025, Pro Medicus remains a formidable player in the healthcare technology space. Established in 1983, the company has been at the forefront of providing advanced radiological IT software to hospitals and imaging centers across the globe. Its flagship product, Visage, allows radiologists to access and interpret large radiological images remotely, enhancing the efficiency of medical diagnostics and potentially improving patient outcomes.
Financially, Pro Medicus has shown impressive growth. Since 2021, the company’s annual revenue growth rate has been 33.4%, climbing to $162 million in FY24. Its net profit surged from $31 million to $83 million over the same period, while the return on equity (ROE) reached a remarkable 50.7%, signaling robust profitability and efficient asset use.
James Hardie Industries plc (ASX:JHX): On the other hand, James Hardie Industries has managed to sustain its operational and financial momentum despite being 46.7% below its 52-week high. As the world's largest producer of fibre cement and gypsum products, James Hardie serves a diverse international market, including North America, Europe, Australia, and New Zealand. The company's products are renowned for their durability, resistance to fire, water, and termites, making them ideal for both residential and commercial construction.
Over the past three years, James Hardie has also reported healthy financial growth. The company's revenue has increased by an average of 10.6% annually, reaching $3.936 billion in FY24. Net profit has nearly doubled from $263 million to $510 million, with an ROE of 29.4%.
Both Pro Medicus and James Hardie Industries demonstrate the significant impact of strategic leadership and innovation in their fields. While the former harnesses technology to improve healthcare outcomes, the latter continues to set standards in building materials that offer safety and sustainability. Investors and market watchers will likely keep a keen eye on these companies as they continue to evolve and adapt in their respective industries.
